research EVIDÊNCIAS ACERCA DO USO DO ANTICORPO MONOCLONAL TOCILIZUMABE COMO TERAPÊUTICA PARA COVID-19
Tocilizumab might be an effective treatment for COVID-19.
Search
for
Sort by
Research
510-540 / 1000+ results research Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
research LB922 CyTOF immune profiling uncovers sex- and race-specific differences and cellular biomarkers for biologic response in Hidradenitis suppurativa
Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.
research Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research 1619 Spatial transcriptomic analysis of imiquimod-treated mouse skin reveals deregulation of lipid raft-associated markers which could be reversed by re-introduction of caveolin scaffolding domain peptide
The research found that a protein called caveolin-1 is reduced in psoriasis, but reintroducing it can help alleviate some psoriasis symptoms.
research Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
research JAK Inhibitors: A New Weapon in the Skin Care Providers' Arsenal.
JAK inhibitors show promise in treating difficult skin diseases.
research The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
research Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
research Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy
Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.
research Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus
Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.
research New drugs: Agalsidase alfa
Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
research Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research Exploring novel management options for alopecia areata
JAK inhibitors can help treat alopecia areata but have risks and high costs.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
research Efficacy of Barictinib As Compared to Conventional Therapy as a Treatment for Alopecia Areata
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
research 3162 Alopecia universalis after alemtuzumab in multiple sclerosis - a nine year follow up and review of literature
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.
research Alopecia universalis treated with bone morphogenetic protein?
A man with alopecia universalis regrew hair temporarily after a bone treatment.
research Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
These new skin treatments are safer and more effective with minimal side effects.
research SnapshotDx Quiz: March 2016
JAK inhibitors may help treat alopecia areata by reversing hair loss.
research Studies on lysosomes—XIII
Stilbamidine and hydroxystilbamidine inhibit enzyme release from lysosomes and have effects similar to cortisol and chloroquine.
research Comparison of effectiveness of weekly azathioprine pulse (WAP) and betamethasone oral mini pulse (BOMP) in the treatment of moderate to severe alopecia areata
Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.
research Severe Pustular Drug Eruptions From Amivantamab: A Case Series
Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.